Journal article icon

Journal article

New developments in the management of psoriasis and psoriatic arthritis: a focus on apremilast.

Abstract:

Psoriasis is a chronic inflammatory skin disease, most commonly resulting in the occurrence of red and silver scaly plaques. About 30% of psoriasis sufferers develop psoriatic arthritis (PsA), a disorder that presents with additional joint inflammation and other clinical features. At present, the most effective treatment for moderate and severe psoriasis and PsA are biologics such as antitumor necrosis factor alpha therapy. Biologics are costly and typically require repeated injections; hence...

Expand abstract
Publication status:
Published

Actions


Access Document


Publisher copy:
10.2147/dddt.s32713

Authors


Palfreeman, AC More by this author
McNamee, KE More by this author
More by this author
Institution:
University of Oxford
Department:
Oxford, MSD, NDORMS
Journal:
Drug design, development and therapy
Volume:
7
Pages:
201-210
Publication date:
2013
DOI:
EISSN:
1177-8881
ISSN:
1177-8881
URN:
uuid:6e8151ec-02f8-46e8-b7d2-0501a00b1ff1
Source identifiers:
395055
Local pid:
pubs:395055

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP